Eikon Therapeutics Inc EIKN
News
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Eikon Therapeutics to Participate in Investor Conferences in September 2026
